Simulación farmacocinética Ivermectina

Ivermectina PO Dosis inicial 800 mg + 400mg q8h

Modelo

- M1: Duthaler U et al.
- M2: El–Tahtawy A et al.
- M3: Smit MR et al.
- M4: Duthaler U et al.

Conc. plasmástica (µg L^{-1})

6000

4000

2000

0

Conc. plasmástica (µM)

6

4

2

0

Tiempo (horas)

0   20   40   60   80

Marc Lavielle (2019). mlxR: Simulation of Longitudinal Data. R package version 4.1.0. https://CRAN.R–project.org/package=mlxR
[M1] Duthaler U, et al. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. Br J Clin Pharmacol. 2019; 85(3):626–33. [M2] El–Tahtawy A et al. The effect of azithromycin on ivermectin pharmacokinetics – A population pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008; 2 (5) [M3] Smit MR, Ochomo EO, Waterhouse D, Kwambai TK, Abong'o BO, Bousema T, et al. Pharmacokinetics –Pharmacodynamics of High–Dose Ivermectin with Dihydroartemisinin–Piperaquine on Mosquitocidal Activity and QT–Prolongation (IVERMAL). Clin Pharmacol Ther. 2019;105(2):388–401. [M4] Duthaler U, Leisegang R, Karlsson MO, Krähenbühl S, Hammann F. The effect of food on the pharmacokinetics of oral ivermectin. J Antimicrob Chemother. 2020;75(2):438–40.